JAMA Oncology (@jamaonc) 's Twitter Profile
JAMA Oncology

@jamaonc

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

ID: 2811548749

linkhttp://ja.ma/tjamaoncology calendar_today15-09-2014 15:33:04

17,17K Tweet

47,47K Followers

542 Following

JAMA Oncology (@jamaonc) 's Twitter Profile Photo
JAMA Oncology
@jamaonc

a year ago

In this study, the endocrine-sensitive disease rate (ESDR) following 6 months of neoadjuvant fulvestrant or anastrozole plus fulvestrant was 22.8% and 20.5%, respectively; neither was significantly higher than the 18.7% ESDR with anastrozole alone. ja.ma/48JWqS0

In this study, the endocrine-sensitive disease rate (ESDR) following 6 months of neoadjuvant fulvestrant or anastrozole plus fulvestrant was 22.8% and 20.5%, respectively; neither was significantly higher than the 18.7% ESDR with anastrozole alone. ja.ma/48JWqS0